Breast Cancer Research and Treatment

, Volume 121, Issue 2, pp 497–502

No evidence for glutathione S-transferases GSTA2, GSTM2, GSTO1, GSTO2, and GSTZ1 in breast cancer risk

Authors

  • Irena E. Andonova
    • Dr. Margarte Fischer-Bosch Institute of Clinical Pharmacology
    • University of Tübingen
    • Department of Medical Chemistry and Biochemistry, Institute of Experimental Pathology and ParasitologyBulgarian Academy of Science and Medical University
  • Christina Justenhoven
    • Dr. Margarte Fischer-Bosch Institute of Clinical Pharmacology
    • University of Tübingen
  • Stefan Winter
    • Dr. Margarte Fischer-Bosch Institute of Clinical Pharmacology
    • University of Tübingen
  • Ute Hamann
    • Molecular Genetics of Breast Cancer, German Cancer Research Center (DKFZ)
  • Christian Baisch
    • Department of Internal MedicineEvangelische Kliniken Bonn gGmbH, Johanniter Krankenhaus
  • Sylvia Rabstein
    • BGFA-Research Institute of Occupational Medicine of the German Social Accident InsuranceRuhr University of Bochum
  • Anne Spickenheuer
    • BGFA-Research Institute of Occupational Medicine of the German Social Accident InsuranceRuhr University of Bochum
  • Volker Harth
    • BGFA-Research Institute of Occupational Medicine of the German Social Accident InsuranceRuhr University of Bochum
  • Beate Pesch
    • BGFA-Research Institute of Occupational Medicine of the German Social Accident InsuranceRuhr University of Bochum
  • Thomas Brüning
    • BGFA-Research Institute of Occupational Medicine of the German Social Accident InsuranceRuhr University of Bochum
  • Yon-Dschun Ko
    • Department of Internal MedicineEvangelische Kliniken Bonn gGmbH, Johanniter Krankenhaus
  • Varban Ganev
    • Faculty of MedicineSofia University St. Kliment Ohridski
    • Dr. Margarte Fischer-Bosch Institute of Clinical Pharmacology
    • University of Tübingen
Epidemiology

DOI: 10.1007/s10549-009-0589-5

Cite this article as:
Andonova, I.E., Justenhoven, C., Winter, S. et al. Breast Cancer Res Treat (2010) 121: 497. doi:10.1007/s10549-009-0589-5

Abstract

Breast cancer is a complex disease and in recent years a number of breast cancer susceptibility genes have been identified, but the role of low penetrance susceptibility genes has not been completely resolved. Glutathione S-transferases (GSTs) are phase II xenobiotic metabolizing enzymes involved in the detoxification of chemical carcinogens and environmental pollutants and play an important role in cell defense mechanisms against oxidative stress. They have been in the spot light for the investigation of a potential association with breast cancer risk but so far, sparse or even no data for a potential contribution of GSTA2, GSTM2, GSTO, and GSTZ to breast cancer risk are available. We genotyped GSTA2_448_C > G (rs2180314), GSTA2_742_A > C (rs6577), GSTM2_-832_T > C (rs638820), GSTO1_-1242_G > A (rs2164624), GSTO1_419_A > C (rs4925), GSTO2_-183_A > G (rs2297235), GSTO2_342_A > G (rs156697), GSTZ1_-4378_A > G (rs1046428), and GSTZ1_94_G > A (rs3177427) by MALDI-TOF MS in the German GENICA breast cancer case–control collection of 1021 cases and 1015 controls and performed breast cancer risk association in general and with respect to the stratifications: menopausal status, family history of breast or ovarian cancer, use of oral contraceptives, use of hormone therapy, body mass index, and smoking as well as histopathological tumor characteristics including hormone receptor status, grade, histology, and node status. We did not observe any breast cancer risk associations and conclude that it is unlikely that glutathione S-transferases GSTA2, GSTM2, GSTO1, GSTO2, and GSTZ1 participate in breast cancer susceptibility.

Keywords

GSTs Polymorphisms Breast cancer risk

Copyright information

© Springer Science+Business Media, LLC. 2009